Europe’s CHMP Clears Just Two Drugs: Brintellix And Opsumit
This article was originally published in The Pink Sheet Daily
Executive Summary
Positive opinions for new medicines were relatively scarce in Europe this month, with only Lundbeck's new antidepressant, Brintellix and Actelion's PAH therapy, Opsumit, being recommended for approval.
You may also be interested in...
Optimal Labeling For Opsumit Allows Actelion To Drop Promotion Of Tracleer
With a ‘clean’ label that differentiates macitentan from current standard of care, Actelion’s got what it wanted from FDA: a newly approved next-generation drug with a long patent life that can expand its presence in the pulmonary arterial hypertension market, and, importantly, protect its core franchise from upcoming generic competition.
Brintellix Label Gives Lundbeck Ground For Tolerability Claims
Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual dysfunction compared to some other drugs.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.